HRAS and head and neck squamous cell carcinoma: This is the use of genetic profiles to identify the selected patients who have the known druggable targets, such as activation of PIK3CA in 34–56% of HNSCC patients and HRAS mutation identified in 5% of HNSCC patients [7].